AbbVie Inc. $ABBV Shares Purchased by RiverFront Investment Group LLC

Key Points

• RiverFront Investment Group boosted its AbbVie stake by 41.7% in the fourth quarter, ending with 30,577 shares valued at about $7.0 million.
• AbbVie beat earnings and revenue estimates in its latest quarterly report, posting $2.65 EPS and $15 billion in revenue, with sales up 12.4% year over year.
• The stock has a Moderate Buy analyst consensus, with a current average target price of $253.43; AbbVie also paid a quarterly dividend of $1.73 per share, equal to a 3.3% yield.

RiverFront Investment Group LLC raised its holdings in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 41.7% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 30,577 shares of the company's stock after purchasing an additional 9,005 shares during the quarter. RiverFront Investment Group LLC's holdings in AbbVie were worth $6,987,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the business. Vanguard Group Inc. grew its stake in AbbVie by 1.7% during the 4th quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company's stock valued at $41,306,353,000 after purchasing an additional 3,032,438 shares in the last quarter. Legal & General Group Plc grew its stake in AbbVie by 4.3% during the 3rd quarter. Legal & General Group Plc now owns 12,004,084 shares of the company's stock valued at $2,779,426,000 after purchasing an additional 493,420 shares in the last quarter. Wellington Management Group LLP grew its stake in AbbVie by 457.4% during the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company's stock valued at $2,439,714,000 after purchasing an additional 8,646,424 shares in the last quarter. Amundi grew its stake in AbbVie by 15.6% during the 3rd quarter. Amundi now owns 10,508,317 shares of the company's stock valued at $2,418,909,000 after purchasing an additional 1,414,621 shares in the last quarter. Finally, Ameriprise Financial Inc. grew its stake in AbbVie by 4.4% during the 3rd quarter. Ameriprise Financial Inc. now owns 9,675,877 shares of the company's stock valued at $2,241,363,000 after purchasing an additional 408,426 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company's stock.

Insider Buying and Selling

In related news, EVP Perry C. Siatis sold 22,381 shares of the business's stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares in the company, valued at $8,771,510. The trade was a 36.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the business's stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president owned 2,654 shares of the company's stock, valued at $619,868.24. This represents a 66.34% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.06% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Citigroup lowered their price objective on AbbVie from $235.00 to $230.00 and set a "neutral" rating for the company in a research note on Tuesday, January 27th. Weiss Ratings restated a "hold (c)" rating on shares of AbbVie in a research note on Wednesday, January 21st. Evercore set a $235.00 target price on AbbVie in a research report on Friday. Sanford C. Bernstein reiterated a "market perform" rating on shares of AbbVie in a research report on Thursday, February 5th. Finally, Guggenheim reiterated a "buy" rating and issued a $249.00 target price on shares of AbbVie in a research report on Friday, May 1st. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, AbbVie currently has a consensus rating of "Moderate Buy" and an average target price of $253.43.

AbbVie Trading Up 0.1%

Shares of ABBV opened at $210.54 on Monday. The firm has a market cap of $371.97 billion, a price-to-earnings ratio of 103.71, a PEG ratio of 0.73 and a beta of 0.32. The stock has a 50 day moving average of $210.27 and a 200-day moving average of $220.05. AbbVie Inc. has a 52 week low of $180.25 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV - Get Free Report) last issued its earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping the consensus estimate of $2.59 by $0.06. The company had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The business's revenue was up 12.4% on a year-over-year basis. During the same quarter last year, the firm earned $2.46 EPS. On average, sell-side analysts predict that AbbVie Inc. will post 14.3 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, May 15th. Investors of record on Wednesday, April 15th were given a dividend of $1.73 per share. The ex-dividend date was Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a yield of 3.3%. AbbVie's payout ratio is currently 340.89%.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s Q1 results were supported by strong sales of Skyrizi and Rinvoq, which helped offset ongoing Humira declines and boosted the company’s 2026 guidance. Article: How Important Are Skyrizi and Rinvoq to AbbVie's Q1 Results?
• Positive Sentiment: Analysts have turned more optimistic on AbbVie’s earnings power, with Erste Group raising FY2027 EPS estimates and the company’s long-term pipeline still viewed favorably. Article: AbbVie analyst estimate update
• Positive Sentiment: Recent commentary highlighted AbbVie as a potentially better growth story than AstraZeneca because of its valuation, dividend profile, and pipeline strength. Article: Which Pharma Giant Offers Better Growth: AstraZeneca or AbbVie?

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.